TWEETS by @pharma_BI and @AVIVA1950 at #IESYMPOSIUM – @kochinstitute 2019 #Immune #Engineering #Symposium, 1/28/2019 – 1/29/2019
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
eProceedings for Day 1 and Day 2
LIVE Day One – Koch Institute 2019 Immune Engineering Symposium, January 28, 2019, Kresge Auditorium, MIT
LIVE Day Two – Koch Institute 2019 Immune Engineering Symposium, January 29, 2019, Kresge Auditorium, MIT
-
AMAZING Conference I covered in Real Time
#Immune#Engineering
-
AMAZING Conference I covered in Real Time
-
LIVE Day One – e-Proceedings
#IESYMPOSIUM@pharma_BI@AVIVA1950@KochInstitute 2019#Immune#Engineering#Symposium, January 28, 2019, Kresge Auditorium, MIT https://pharmaceuticalintelligence.com/2019/01/28/live-day-one-koch-institute-2019-immune-engineering-symposium-january-28-2019-kresge-auditorium-mit/ … via@Pharma_BILIVE Day Two – Koch Institute 2019 Immune Engineering Symposium, January 29, 2019, Kresge Auditorium, MIT http://pharmaceuticalintelligence.com/2019/01/29/live-day-two-koch-institute-2019-immune-engineering-symposium-january-29-2019-kresge-auditorium-mit/ …
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Aviv Regev@kochinstitute Melanoma: malignant cells with resistance in cold niches in situ cells express the resistance program pre-treatment: resistance UP – cold Predict checkpoint immunotherapy outcomes CDK4/6 abemaciclib in cell lines -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Aviv Regev,@broadinstitute@kochinstitute#Cell#atlases a#Cancer cell-cell interactions from variations across individuals Most UC-risk genes are cell type specificVariation – epithelial cell signature – organize US GWAS into cell type spec -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Diane Mathis@HMS Age-dependent Treg and mSC changes – Linear with increase in age Sex-dependent Treg and mSC changes – Female Treg loss in cases of Obesity leading to fibrosis Treg keep IL-33-Producing mSCs under rein Lean tissue/Obese tissue -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Martin LaFleur@HMS Loss of Ptpn2 enhances CD8+ T cell responses to LCMV and Tumors PTpn2 deletion in the immune system enhanced tumor immunity CHIME enables in vivo screening -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Alex Shalek@MIT@kochinstitute Identifying and rationally modulating cellular drivers of enhanced immunity T Cells, Clusters Expression of Peak and Memory Immunotherapy- Identifying Dendritic cells enhanced in HIV-1 Elite Controllers -
-
You Retweeted
Onward: our own Michael Birnbaum, who assures us that if you feel like you’re an immunoengineer, then you ARE one!
@kochinstitute -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Glenn Dranoff@Novartis Adenosine level in blood or tissue very difficult to measure in blood even more than in tissue – NIR178 + PDR 001 Monotherapy (NIR178) combine with PD receptor blockage (PDR) show benefit A alone vs A+B in Clinical trial -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Glenn Dranoff@Novartis PD-L1 blockade elicits responses in some patients: soft part sarcoma LAG-3 combined with PD-1 – human peripheral blood tumor TIM-3 key regulator of T cell and Myeloid cell function: correlates in the TCGA DB myeloid -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Glenn Dranoff@Novartis Institute for Biomedical Research#Mechnism of#protective#tumor#immunity Neurologic toxicities of CART t IL-6 activation AML – complete response – weekly dose of XmAb CD123X CD3 bispecific antibody anti tumor effect -
#IESYMPOSIUM@pharma_BI@AVIVA1950@michaelbirnbaum@MIT@kochinstitute#repertoire of protective#tumor#immunity HLA-DR4 effects outside of “peptide anchor” residues Class I MHC – HLA-E down regulate T and NK cells Receptor Binding: Positional preferences noted for NKG2A -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Yvonne Chen@UCLA Activation of t Cell use CAR t Engineer CAR-T to respond to soluble form of antigens: CD19 CAR Responds to soluble CD19 GFP MCAR responds to Dimeric GFP “Tumor microenvironment is a scary place” -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Yvonne Chen@UCLA Do we need a ligand to be a dimers? Co-expressed second-generation TGF-beta signaling
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Yvonne Chen@UCLA “Engineering smarter and stronger T cells for cancer immunotherapy” OR-Gate cause no relapse – Probing limits of modularity in CAR Design Bispecific CARs are superior to DualCAR: One vs DualCAR (some remained single CAR) -
You Retweeted
Ending the 1st session is Cathy Wu of
@DanaFarber detailing some amazing work on vaccination strategies for melanoma and glioblastoma patients. They use long peptides engineered from tumor sequencing data.#iesymposium -
You Retweeted
Some fancy imaging: Duggan gives a nice demo of how dSTORM imaging works using a micropatterend image of Kennedy Institute for Rheumatology! yay!
#iesymposium -
You Retweeted
Lots of interesting talks in the second session of the
#iesymposium – effects of lymphoangiogenesis on anti-tumor immune responses, nanoparticle based strategies to improve bNAbs titers/affinity for HIV therapy, and IAPi cancer immunotherapy -
You Retweeted
Looking forward to another day of the
#iesymposium. One more highlight from yesterday –@nm0min from our own lab showcased her work developing cytokine fusions that bind to collagen, boosting efficacy while drastically reducing toxicities
-
You Retweeted
Members of our cell therapy team were down the street today at neighboring
@MIT for the#iesymposium presented by@kochinstitute.#CRISPR#genomeediting
-
You Retweeted
He could have fooled me that he is, in fact, an immunologist!
-
-
You Retweeted
I absolutely LOVE this essay. “Why geneticists stole cancer research even though cancer is primarily a signaling disease”
-
You RetweetedMore
Come and say Hi! ACIR will be back tomorrow at the Immune Engineering Symposium at MIT. Learn more at http://ow.ly/gk9430ns0QX .
#iesymposium@kochinstitute. And stay tuned to read our summary of the talks on Feb 6.#subscribe#newsletter#IO#free
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Facundo Batista @MGH#Vaccine ##evaluation in#humanized#mousemodels BG18 Germline Heavy CHain (BG18-gH) High-mannose patch – mice exhibit normal B cell development B cells from naive human germline BG18-gH bind to GT2 immunogen -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Preeti Sharma, U Illinois T cell receptor and CAR-T engineering TCR engineering for Targeting glycosylated cancer antigens Nornal glycosylation vs Aberrant Engineering 237-CARs libraries with conjugated (Tn-OTS8) against Tn-antigend In vitro -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Bryan Bryson@MIT Loss of polarization potential: scRNAseq reveals transcriptional differences Thioredoxin facilitates immune response to Mtb is a marker of an inflammatory macrophage state functional spectrum of human microphages -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Bryan Bryson@MIT macrophage axis in Mycobacterium tuberculosis Building “libraries” – surface marker analysis of Microphages Polarized macrophages are functionally different quant and qual differences History of GM-CSF suppresses IL-10 -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Jamie Spangler John Hopkins University “Reprogramming anti-cancer immunity RESPONSE through molecular engineering” De novo IL-2 potetiator in therapeutic superior to the natural cytokine by molecular engineering mimicking other cytokines -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Jamie Spangler@JHU JES6-1 Immunocytokine – inhibiting melanoma Engineering a Treg cell-biased immunocytokine double mutant immunocytokine shows enhanced IL-2Ralpha exchange Affinity De Novo design of a hyper-stable, effector biased IL-2 -
#Cardiovascular#Diseases, Volume Six:#Interventional#Cardiology for#disease#diagnosis and#Cardiac#Surgery for#Condition#Treatment. On com since 12/24/2018 https://lnkd.in/e_CTb4R@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Five:#PharmacologicalAgents in#Treatment of Cardiovascular Diseases. On com since 12/23/2018 https://lnkd.in/e3r87cQ@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Four:#Regenerative and#Translational#medicine : The#Therapeutics#Promise for Cardiovascular Diseases. On com since 12/26/2015 https://lnkd.in/dwqM3K3@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Three:#Etiologies of#Cardiovascular Diseases:#Epigenetics,#Genetics and#Genomics. On com since 11/29/2015 https://lnkd.in/ecp5mrA@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Two: Cardiovascular#Original#Research: Cases in#Methodology Design for#Content Co-Curation. On com since 11/30/2015 https://lnkd.in/ekbuNZ3@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume One:#Perspectives on#Nitric#Oxide in#Disease#Mechanisms. On com since 6/21/2013 https://lnkd.in/8DANfq@pharma_BI@AVIVA1950 -
#IESYMPOSIUM@pharma_BI@AVIVA1950 eProceeding LIVE Day One@KochInstitute@MIT 2019#Immune#Engineering#Symposium, January 28, 2019, Kresge Auditorium, MIT https://pharmaceuticalintelligence.com/2019/01/28/live-day-one-koch-institute-2019-immune-engineering-symposium-january-28-2019-kresge-auditorium-mit/ … via@Pharma_BI -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Michael Dustin@UniofOxford ESCRT pathway associated with synaptic ectosomes Locatization, Microscopy Cytotoxic T cell granules CTLs release extracellular vescicles similar to T Helper with perforin and granzyme – CTL vesicles kill targets -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Michael Dustin@Oxford Delivery of T cell Effector function through extracellular vesicles Synaptic ectosome biogenisis Model: T cells: DOpamine cascade in germinal cell delivered to synaptic cleft – Effector CD40 – Transfer is cooperative -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Michael Dustin@Oxford Delivery of T cell Effector function through extracellular vesicles Laterally mobile ligands track receptor interaction ICAM-1 Signaling of synapse – Sustain signaling by transient in microclusters TCR related Invadipodia -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Mikael Pittet @MGH Myeloid Cells in Cancer Indirect mechanism AFTER a-PD-1 Treatment IFN-gamma Sensing Fosters IL-12 & therapeutic Responses aPD-1-Mediated Activation of Tumor Immunity – Direct activation and the ‘Licensing’ Model -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Stefani Spranger@MIT KI Response to checkpoint blockade Non-T cell-inflamed – is LACK OF T CELL INFILTRATION Tumor CD103 dendritic cells – Tumor-residing Batf3-drivenCD103 Tumor-intrinsic Beta-catenin mediates lack of T cell infiltration -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Max Krummel@UCSF Gene expression association between two genes:#NK and#cDC1 numbers are tightly linked to response to checkpoint blockage IMMUNE “ACCOMODATION” ARCHYTYPES: MYELOID TUNING OF ARCHITYPES Myeloid function and composition -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Noor Momin, MIT Lumican-cytokines improve control of distant lesions – Lumican-fusion potentiates systemic anti-tumor immunityTranslate Tweet
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Noor Momin, MIT Lumican fusion to IL-2 improves treatment efficacy reduce toxicity – Anti-TAA mAb – TA99 vs IL-2 Best efficacy and least toxicity in Lumican-MSA-IL-2 vs MSA-IL2 Lumican synergy with CAR-T -
You Retweeted
excited to attend the
@kochinstitute@MIT immune engineering symposium#iesymposium this week! find me there to chat about@CellCellPress and whether your paper could be a good fit for us!
-
You Retweeted
Bob Schreiber and Tyler Jacks kicked off the
#iesymposium with 2 great talks on the role of Class I and Class II neo-Ag in tumor immunogenicity and how the tumor microenvironment alters T cell responsiveness to tumors in vivo -
You Retweeted
Scott Wilson from
@UChicago gave a fantastic talk on glycopolymer conjugation to antigens to improve trafficking to HAPCs and enhanced tolerization in autoimmunity models. Excited to learn more about his work at his@MITChemE faculty talk!#iesymposium -
-
You Retweeted
Immune Engineering Symposium at MIT is underway!
#iesymposium@kochinstitute
-
You RetweetedMore
ACIR is excited to be covering the Immune Engineering Symposium at MIT on January 28-29. Learn more at http://ow.ly/gk9430ns0QX .
#iesymposium@kochinstitute
-
Tyler Jacks talk was outstanding, Needs be delivered A@TED TALKs, needs become contents in the curriculum of Cell Biology graduate seminar as an Online class. BRAVO
@pharma_BI@AVIVA1950
-
You Retweeted
Here we go!! Today and tomorrow the tippity top immunologists converge at
@MIT@kochinstitute#iesymposium
-
You Retweeted
Exciting start to this year’s Immune Engineering Symposium put on by
@kochinstitute at@MIT. A few highlights from the first section…#iesymposium -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Stephanie Dougan (Dana-Farber Cancer Institute) Dept. Virology IAPi outperforms checkpoint blockade in T cell cold tumors reduction of tumor burden gencitabine cross-presenting DCs and CD8 T cells – T cell low 6694c2 -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Darrell Irvine (MIT, Koch Institute; HHMI) Engineering follicle delivery through synthetic glycans: eOD-60mer nanoparticles vs Ferritin-trimer 8-mer (density dependent) -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Darrell Irvine (MIT, Koch Institute; HHMI) GC targeting is dependent on complement component CIQ – activation: Mannose-binding lectins recognize eOD-60mer but not eOD monomer or trimers -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Melody Swartz (University of Chicago) Lymphangiogenesis attractive to Native T cells, in VEGF-C tumors T cell homing inhibitors vs block T cell egress inhibitors – Immunotherapy induces T cell killing -
Paradigm shift
#antigens vs#neoantigens#IESYMPOSIUM@pharma_BI@AVIVA1950
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Cathy Wu @MGH breakthrough for Brain Tumor#vaccine based neoantigen-specific T cell at intracranial site Single cells brain tissue vs single cells from neoantigen specific T cells – intratumoral neoantigen-specific T cells: mutARGAP35-spacific -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Cathy Wu (Massachusetts General Hospital) – CoFounder of NEON Enduring complete radiographic responses after#Neovax + alpha-PD-1 treatment (anti-PD-1) NeoVax vs IVAC Mutanome for melanoma and Glioblastoma clinical trials -
#IESYMPOSIUM@pharma_BI@AVIVA1950@ScottWilson, U of Chicago IV INJECTION: OVAALBUMIN OVA-P(GALINAC), P(GLCNAC), SUPRESS T CELL RESPONSE#Glycoconjucates Abate T cells response – Reduced cytokine production & increased#T-regs -
#IESYMPOSIUM@pharma_BI@AVIVA1950@TylerJacks@MIT Interrogating markers of T cell dysfunction – chance biology of cells by CRISPR – EGR2 at 2 weeks dysfuntioning is reduced presence of EDR2 mutant class plays role in cell metabolism cell becomes functional regulator CD8 T cell -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Bob Schreiber (Wash University of St. Louis) Optimal CD8+ T cells mediated#immuneresponses to T3#sarcomas require CD4+ T#cell help
2012pharmaceutical
Aashir Awan, Phd
Alan F. Kaul, PharmD., MS, MBA, FCCP
amnondanzig1724
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
evelinacohn
Gail S Thornton
Irina Robu
jdpmd
kellyperlman
Ed Kislauskis
larryhbern
lmulligan13gmailcom
marzankhan
megbaker58
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22